HUNTINGTON BEACH, California – May 9th, 2026 — Lionheart Health, Inc. announced today a new provisional patent application covering bioelectric modulation and expression of HMGB1 (High Mobility Group Box 1 protein) for applications in tissue regeneration, stem cell homing, neuroregeneration, muscle recovery, joint repair, longevity optimization and performance enhancement.
The patent filing expands Lionheart Health’s growing intellectual property portfolio in bioelectric protein expression technologies designed to non-invasively stimulate regenerative pathways within the body.
HMGB1 is increasingly recognized as a key signaling protein involved in tissue repair, stem cell migration, angiogenesis, and regenerative healing responses. Emerging research suggests that specific forms of HMGB1 may accelerate endogenous regeneration while minimizing inflammatory signaling.
The Lionheart patent filing covers methods and devices intended to:
• Increase regenerative HMGB1 signaling using targeted bioelectric stimulation
• Enhance stem cell homing and tissue repair
• Combine HMGB1 stimulation with stem cells, exosomes, PRF, peptides, PEMF, red light and ultrasound
• Create tissue-specific regeneration programs for brain, muscle, joints, skin, hair, heart and sexual health
• Utilize wearable and implantable bioelectric systems for long-term regenerative support
• Integrate HMGB1 modulation with Klotho, sestrins, sirtuins, BDGF, Apelin, GDF10, Tropoelastin, SDF1, PDGF and other regenerative proteins
Applications under development include:
• Brain Band™ neuroregeneration programs
• OrthoStim™ joint regeneration
• HairCell™ hair restoration
• SkinStim™ skin regeneration
• BodStim™ muscle optimization and recovery
• EyeCell™ and EarCell™ sensory regeneration platforms
• Lionheart Octopus™ implantable regeneration systems
According to Lionheart Health Executive Chairman Howard J. Leonhardt: “HMGB1 appears to act as an important regenerative signaling switch under the right conditions. Our goal is to use precise bioelectric signaling to enhance regenerative forms of HMGB1 while minimizing harmful inflammatory responses. We believe this could become an important component of future regenerative medicine and longevity optimization.”
The company believes the patent filing strengthens its position in the rapidly emerging field of bioelectric protein expression therapeutics.
HMGB1 mechanism summary
HMGB1 is a context-dependent “damage-and-repair” protein: inside the nucleus it supports chromatin structure and DNA repair; in the cytoplasm it can regulate autophagy; and when released extracellularly after stress, injury, senescence, ischemia, or immune activation, it acts as a DAMP signal through receptors including RAGE, TLR2 and TLR4, activating NF-κB, MAPK, JAK/STAT, inflammasome and cytokine pathways. Its effect depends heavily on dose, location, timing and redox state: controlled/reduced HMGB1 signaling may support tissue repair, stem/progenitor-cell recruitment, angiogenesis and muscle remodeling, while chronic extracellular HMGB1 may drive inflammaging, fibrosis, neuroinflammation, vascular injury and senescence spread. The connection to Klotho appears mainly indirect but strategically important: HMGB1 tends to activate inflammatory NF-κB/RAGE/TLR4 biology, while Klotho is broadly described as anti-aging and anti-inflammatory; one melanoma study reported that HMGB1 knockdown increased Klotho protein and reduced p-NF-κB, suggesting a possible HMGB1–NF-κB–Klotho inverse relationship. Therefore, the strongest Lionheart framing is not simply “increase HMGB1,” but bioelectrically tune HMGB1 toward acute regenerative repair signaling while pairing it with Klotho-supportive, anti-inflammatory, anti-fibrotic and senescence-limiting pathways.
Reference list: HMGB1, healthspan, longevity and organ health
- HMGB1, an evolving pleiotropic protein critical for cellular and tissue homeostasis: Role in aging and age-related diseases — directly relevant overview tying HMGB1 to aging biology and age-related disease.
- The multifunctional protein HMGB1: 50 years of discovery — major Nature Reviews Immunology review describing HMGB1 roles in DNA repair, autophagy, innate immunity, tissue maintenance, cardiovascular disease, neurodegeneration, metabolic disorders and cancer.
- The mechanism of HMGB1 secretion and release — explains nuclear, cytoplasmic and extracellular HMGB1 functions, including DAMP signaling, inflammation and tissue damage.
- The Ambiguous Role of HMGB1 Across the Hallmarks of Aging — 2025 review connecting HMGB1 to genomic instability, senescence, inflammaging and aging hallmarks.
- This blood protein could be spreading aging throughout your body — summary of peer-reviewed work identifying reduced HMGB1 as a circulating SASP factor that can transmit senescence to distant tissues.
- High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle — important muscle-regeneration reference cited within the HMGB1 secretion review.
- Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease — review describing HMGB1’s role in renal homeostasis, CKD progression and kidney prognosis.
- Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma through activation of NF-κB — direct HMGB1–Klotho connection; knockdown of HMGB1 increased Klotho protein and reduced p-NF-κB.
- Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations — useful companion reference for the Klotho side of the mechanism; Klotho is described as anti-aging and as inhibiting TGF-β, IGF-1, Wnt and other aging-linked pathways.
- The Klotho proteins in health and disease — broad reference on αKlotho/βKlotho biology and health relevance.
For more information visit: